p53-Mdm2-the affair that never ends

Carcinogenesis

Volumn 23, Issue 4, 2002, Pages 541-547

  Alarcon Vargas, Dania ^a   Ronai, Ze've ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL MATURATION; CONFORMATION; GENE ACTIVITY; GENE FUNCTION; GENE INTERACTION; GENETIC STABILITY; GROWTH REGULATION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR SUPPRESSOR GENE;

EID: 0036247821     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.4.541     Document Type: Article

References (137)

1. The p53 pathway
2. p53: Integrating the complexity
3. P53: Puzzle and paradigm
4. p53: The cellular gatekeeper for growth and division
5. The p53 network
6. p53 tumor suppressor gene: From the basic research laboratory to the clinic-an abridged historical perspective
7. The p53 tumor suppressor gene and tumor prognosis: Is there a relationship?
8. Definition of a consensus binding site for p53
9. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage
10. Post-translational modification of p53
11. DNA damage induces phosphorylation of the amino terminus of p53
12. DNA damage activates p53 through a phosphorylation-acetylation cascade
13. How to activate p53
14. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response tumor cells
15. Regulation of the specific DNA binding function of p53
16. Regulation of p53 downstream genes
17. Potential roles for p53 in nucleotide excision repair
18. Participation of p53 protein in the cellular response to DNA damage
19. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
20. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
21. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression
22. A model for p53-induced apoptosis
23. Identification of redox/repair protein Ref-1 as an activator of p53
24. The cellular response to p53: The decision between life and death
25. Conformation-dependent phosphorylation of p53
26. Stress signals utilize multiple pathways to stabilize p53
27. Post-translational modifications and activation of p53 by genotoxic stresses
28. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
29. MEKK1/JNK signaling stabilizes and activates p53
30. Stabilization and activation of p53 are regulated independently by different phosphorylation events
31. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
32. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
33. DNA damage-inducible activation of p53 by the checkpoint kinase Chk2
34. p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p3000/CBP during the cell cycle and after exposure to ultraviolet irradiation
35. DNA damage induces phophorylation of the amino terminus of p53
36. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by casein 1-like kinase. Effect on Mdm2 binding
37. Human p53 is phosphorylated on seines 6 and 9 in response to DNA damage inducing agents
38. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
39. Signaling to p53: Breaking the posttranslational modification code
40. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
41. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress
42. Mutation of phosphoserine 389 affects p53 function in vivo
43. The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II
44. Phosphorylation of human p53 on Thr-55
45. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system
46. JNK targets p53 ubiquitination and degradation in nonstressed cells
47. DNA damage-induced phosphorylation of p53 alleviates inhibition by mdm2
48. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress
49. The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53
50. Distinct pattern of p53 phosphorylation in human tumors
51. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability
52. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells
53. Latent and active p53 are identical in conformation
54. Activation or p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
55. Binding and modulation of p53 by p300/CBP coactivators
56. Transcriptional repression by wild type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
57. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage
58. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53
59. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1
60. SUMO-1 modification activates the transcriptional response of p53
61. c-Jun and p53 activity is modulated by SUMO-1 modification
62. Functional analysis and intracellular localization of p53 modified by SUMO-1
63. Involvement of PIAS1 in the sumoylation of tumor suppressor p53
64. Database of p53 gene somatic mutations in human tumors and cell lines
65. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
66. p53 mutations: Gains or losses?
67. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
68. Mutant p53; 'gain of function' through perturbation of nuclear structure and function
69. On the expression of the p53 protein in human cancer
70. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha
71. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis
72. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins
73. Stabilization and activation of p53 by the coactivator protein TAFII31
74. Modulation of p53 protein expression during cellular transformation with simian virus 40
75. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
76. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status
77. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line
78. Amplification of a gene encoding a p53-associated protein in human sarcomas
79. The MDM2 gene amplification database
80. MDM2 oncogene as a novel target for human cancer therapy
81. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
82. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities
83. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
84. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
85. Oncoprotein MDM2 is a ubiqutin ligase E3 for tumor suppressor p53
86. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53
87. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase
88. Mdm2 promotes the rapid degradation of p53
89. Regulation of p53 stability by Mdm2
90. Mdm2 association with p53 targets its ubiquitination
91. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53
92. The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9
93. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
94. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
95. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
96. p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation
97. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus
98. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins
99. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation
100. Multiple sites of in vivo phosphorylation in the MSN2 oncoprotein cluster within two important functional domains
101. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53
102. Cyclin a-cdk phosphorylation regulates mdm2 protein interactions
103. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage
104. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
105. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation
106. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation
107. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
108. p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53
109. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
110. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer
111. Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone
112. The Mdm2 oncoprotein interacts with the cell fate regulator Numb
113. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2
114. Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin
115. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2
116. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
117. Apoptotic and growth-promoting activity of E2F modulated by MDM2
118. P300/MDM2 complexes participate in Mdm2-mediated p53 degradation
119. Recruitment of p300/CBP in p53-dependent signal pathways
120. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
121. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
122. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
123. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
124. Nucleolar Arf sequesters Mdm2 and activates p53
125. The p53-mdm-2 autoregulatory feedback loop
126. Bates functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
127. MDMX: A novel p53-binding protein with some functional properties of MDM2
128. MDM2 and MDMX inhibits the transcriptional activity of ectopically expressed SMAD proteins
129. Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein
130. MdmX protects p53 from Mdm2-mediated degradation
131. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
132. Excess beta-catenin promotes accumulation of transcriptionally active p53
133. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation
134. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF
135. A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection
136. Exploiting the p53 pathway for cancer diagnosis and therapy
137. Strategies for manipulating the p53 pathway in the treatment of human cancer